This Month in JNM

October 1, 2020

Editor’s Page—Toward accurate in vivo diagnosis of Alzheimer Disease: Barthel discusses approval of the first tau PET tracer. Page 1409

Editorial—FDA-approved brain tau imaging: Mattay and colleagues from the FDA summarize the evidence and clinical data supporting recent approval of 18F-flortaucipir for PET in Alzheimer disease evaluation. Page 1411

The State of the Art—AD and neuropathic imaging changes: Koychev and colleagues review 3 elements that define the National Institute on Aging–Alzheimer’s Association scoring system and discuss ways in which these relate to findings in amyloid-β and tau PET scintigraphy. Page 1413

Continuing Education—Principles of optical imaging modalities: Pirovano and colleagues provide an educational overview of emerging optical strategies for molecular imaging, including established and future applications and rationales for selection of appropriate optical technologies. Page 1419

Future of molecular imaging: Grimm and colleagues offer perspective on current promising research and clinical directions for molecular imaging, with foci on associated imaging without probes, with new radiotracers and small molecules, and in nano- and microsystems. Page 1428

c-Met fluorescence molecular endoscopy: de Jongh and colleagues determine the optimal dose-to-imaging interval and safety of fluorescence molecular endoscopy using EMI-137, a c-Met–targeted fluorescent peptide, in patients at high risk for colorectal cancer. Page 1435

PET/CT in cervical cancer: Leray and colleagues use 18F-FDG PET/CT to identify a high-risk subgroup requiring therapeutic intensification among patients with locally advanced cervical cancer and paraaortic lymph node involvement. Page 1442

dPET performance in cancer: Koopman and colleagues evaluate a PET system using silicon photomultipliers with digital readouts in patients with cancer and compare the results with those from high-resolution conventional PET imaging. Page 1448

Quantifying PD-L1 expression: Huisman and colleagues report on a technique for quantification of uptake of 18F-BMS-986192, a programmed cell death ligand–1 adnectin PET tracer, in patients with non–small cell lung cancer. Page 1455

Clinical translation of 68Ga-cycratide: Feng and colleagues detail the development and early preclinical and clinical assessment of a 68Ga-labeled integrin αvβ6–targeting cyclic peptide for PET imaging of pancreatic cancer. Page 1461

Featured Basic Science Article—177Lu-lilotomab radioimmunotherapy for NHL: Malenge and colleagues explore the potential of this next-generation β-particle–emitting radioimmunoconjugate to reverse rituximab resistance in both in vitro and preclinical non-Hodgkin lymphoma studies. Page 1468

Early PSA changes and 177Lu-PSMA therapy: Gafita and colleagues evaluate the prognostic value of early prostate-specific antigen changes during 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with metastatic castration-resistant prostate cancer. Page 1476

Multiphasic PSMA PET/CT: Beheshti and colleagues determine the impact of multiphasic acquisition of 68Ga-PSMA PET/CT in detection of recurrent prostate cancer in patients with early biochemical recurrence and prostate-specific antigen levels <1 ng/mL. Page 1484

64Cu-DOTATATE PET/CT and prognosis: Carlsen and colleagues look at the association of 64Cu-DOTATATE PET somatostatin receptor imaging with overall and progression-free survival in patients with neuroendocrine neoplasms. Page 1491

Surgical perspectives on CLI: Bagguley and colleagues provide current supporting evidence for and challenges in the use of Cerenkov luminescence imaging for avoidance of positive surgical margins in radical prostatectomy. Page 1498

Featured Article of the Month—Cerenkov luminescence in prostatectomy: Darr and colleagues report on the feasibility and accuracy of Cerenkov luminescence imaging for assessment of surgical margins intraoperatively during radical prostatectomy in patients with high-risk primary prostate cancer. Page 1500

99mTc-labeled FAPI tracers: Lindner and colleagues explore the devlopment and potential of 99mTc–fibroblast-activating protein inhibitors as tracers for diagnostic scintigraphy, especially where PET imaging is not available. Page 1507

OpenDose collaboration: Chauvin and an international consortium report on this collaboration to generate and make available a range of dosimetric data and tools, including display and downloading of specific absorbed fractions and corresponding S values for 1,252 radionuclides. Page 1514

Data-driven gating for CBM PET/CT: Büther and colleagues investigate a continuous-bed-motion‒capable data-driven PET gating algorithm in a clinical cohort and compare the results with pressure-sensitive belt gating, using optimally gated and fully motion-corrected reconstructions. Page 1520

Prism-PET: LaBella and colleagues introduce a single-ended-readout PET detector module with a segmented light guide composed of an array of prismatoids that introduce enhanced, deterministic light sharing. Page 1528

Nuclear cardiology during COVID-19: Skali and representatives from multiple professional organizations offer joint guidance and best practices for reestablishment of nonemergent care in nuclear cardiology laboratories during the COVID-19 pandemic. Page 1534